tiprankstipranks
Trending News
More News >
Electromed (ELMD)
XASE:ELMD
US Market

Electromed (ELMD) Earnings Dates, Call Summary & Reports

Compare
256 Followers

Earnings Data

Report Date
May 12, 2026
After Close (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
0.24
Last Year’s EPS
0.21
Same Quarter Last Year
Based on 3 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Feb 10, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and financial picture: record revenue growth, meaningful margin expansion, robust home-care execution, and multiple strategic initiatives (payer contracts, digital order flow, CRM, manufacturing optimization). The main negatives are a decline in hospital and other revenues, a one-time-like cash reduction driven by share repurchases, higher SG&A tied to growth investments, and a meaningful market education gap (58% of qualifying patients not receiving therapy). Taken together, the positives (sustained top-line growth, improved profitability, balance sheet strength, and clear large addressable market) materially outweigh the near-term challenges and risks discussed.
Company Guidance
Electromed reiterated forward-looking targets of double-digit top-line growth and expanded operating leverage for the coming quarters and full FY2026, while planning to grow its direct sales force from an average of 58 reps in Q2 to 61 reps by year-end (annualized home care revenue per rep target $1.0–$1.1M, versus $1.2M achieved in Q2), and to sustain mid-70%+ gross margins (Q2 gross margin 78.4%). Management also signaled confidence in capital allocation with a $10.0M stock repurchase authorization ( ~$3.8M repurchased in the six months), a strong balance sheet (cash $13.8M, no debt, working capital $36.2M, shareholders’ equity $45.4M), and continued payer expansion (25 contracts adding 2.9M covered lives to >270M). Operational levers highlighted to drive the guidance include continued Smart Order adoption (over one-third of Q2 orders), CRM-driven sales productivity gains, completed manufacturing optimization, and an expectation that hospital demand (hospital revenue $0.7M, down 9.4% in Q2) will rebound.
Record Revenue and Continued Growth Streak
Net revenue of $18.9M in Q2 FY2026, a 16.3% year-over-year increase; marks the thirteenth consecutive quarter of year-over-year revenue and profit growth.
Strong Home Care Performance
Direct Home Care revenue grew 18.4% YoY to $17.3M; annualized home care revenue per weighted-average direct sales representative reached $1.2M (above target range of $1.0M–$1.1M); averaged 58 direct reps in Q2 with planned expansion to 61.
Improved Profitability and Margins
Gross profit increased to $14.8M (78.4% of net revenues) from $12.6M (77.7% prior year). Operating income rose ~42.4% YoY (CFO reported operating income of $3.6M or 19.2% of sales vs $2.5M prior year). Net income grew 40.3% YoY to $2.8M; diluted EPS $0.32 vs $0.22 prior year.
Balance Sheet Strength
Cash on hand of $13.8M, no debt, working capital of $36.2M, and total shareholders' equity of $45.4M.
Shareholder Return Initiatives
Board approved a $10M stock repurchase authorization (authorized in Q1); $3.8M of share repurchases executed in the six months ended Dec 31, 2025.
Commercial and Market Expansion Wins
Executed 25 payer contracts in H1 FY2026, adding ~2.9M covered lives to the company's >270M already under contract; home care distributor channel grew 12.1% YoY to $900K.
Operational and Go-to-Market Enhancements
Completed manufacturing optimization (US-based operations and assembly), implemented CRM and Smart Order e-prescribe (over one-third of orders on e-prescribe in Q2), and engaged in marketing/education (3 national trade shows, regional events, and 3 virtual CEUs with 655 attendees).
Large Addressable Opportunity Identified
Company highlights ~923,000 diagnosed bronchiectasis patients in the U.S. with only 16% using HFCWO therapy; estimates suggest >4M undiagnosed individuals — framing a substantial long-term market opportunity.

Electromed (ELMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ELMD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 12, 2026
2026 (Q3)
0.24 / -
0.21
Feb 10, 2026
2026 (Q2)
0.26 / 0.32
0.2245.45% (+0.10)
Nov 12, 2025
2026 (Q1)
0.20 / 0.25
0.1656.25% (+0.09)
Aug 26, 2025
2025 (Q4)
0.22 / 0.25
0.225.00% (+0.05)
May 13, 2025
2025 (Q3)
0.20 / 0.21
0.1723.53% (+0.04)
Feb 11, 2025
2025 (Q2)
0.18 / 0.22
0.1915.79% (+0.03)
Nov 12, 2024
2025 (Q1)
0.03 / 0.16
0.02700.00% (+0.14)
Aug 27, 2024
2024 (Q4)
0.14 / 0.20
0.1266.67% (+0.08)
May 07, 2024
2024 (Q3)
0.13 / 0.17
0.1241.67% (+0.05)
Feb 13, 2024
2024 (Q2)
0.10 / 0.19
0.1172.73% (+0.08)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ELMD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 10, 2026
$28.06$25.26-9.98%
Nov 12, 2025
$25.38$26.35+3.82%
Aug 26, 2025
$20.66$24.77+19.89%
May 13, 2025
$22.83$19.34-15.29%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Electromed (ELMD) report earnings?
Electromed (ELMD) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
    What is Electromed (ELMD) earnings time?
    Electromed (ELMD) earnings time is at May 12, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ELMD EPS forecast?
          ELMD EPS forecast for the fiscal quarter 2026 (Q3) is 0.24.